Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 5/20 | 0.60 |
| ▸ | EGFR | P00533 | 4/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.54 |
| ▸ | INSR | P06213 | 2/20 | 0.54 |
| ▸ | IGF1R | P08069 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | ROS1 | P08922 | 1/20 | 0.54 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.54 |
| ▸ | ULK1 | O75385 | 1/20 | 0.52 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26778462 | 0.81 | ALK (0.62) | PLK1EGFRALKINSRIGF1R | |
| SCHEMBL26778361 | 0.81 | ALK (0.61) | PLK1EGFRALKINSRIGF1R | |
| SCHEMBL24328343 | 0.80 | EGFR (0.54) | PLK1EGFRALKIGF1RAURKA | |
| SCHEMBL24326974 | 0.78 | EGFR (0.74) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL24327368 | 0.78 | EGFR (0.59) | PLK1EGFRALKINSRIGF1R | |
| SCHEMBL3760012 | 0.77 | PLK1 (0.64) | PLK1EGFRALKINSRIGF1R | |
| SCHEMBL29216391 | 0.77 | EGFR (0.72) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL30141622 | 0.77 | EGFR (0.72) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL26378989 | 0.76 | PLK1 (0.63) | PLK1EGFRALKINSRIGF1R | |
| SCHEMBL3766371 | 0.76 | PLK1 (0.62) | PLK1EGFRALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| WO-2022063106-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEIGENE, LTD. (KY) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | PLK1 101/4885EGFR 1/4885ALK 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.